Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview

[1]  C. Loprinzi,et al.  Recent Developments of Novel Pharmacologic Therapeutics for Prevention of Chemotherapy-Induced Peripheral Neuropathy , 2019, Clinical Cancer Research.

[2]  A. Molassiotis,et al.  Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy , 2019, Brain and behavior.

[3]  H. Jim,et al.  A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer. , 2019, Gynecologic oncology.

[4]  Andreas C. Themistocleous,et al.  Using stratified medicine to understand, diagnose, and treat neuropathic pain. , 2018, Pain.

[5]  Smita H. Karande,et al.  Pharmacogenomics of Vincristine‐Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes , 2018, Clinical pharmacology and therapeutics.

[6]  H. Tamim,et al.  Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study , 2018, Pharmacogenetics and genomics.

[7]  M. Wallhagen,et al.  Impact of chemotherapy-induced neurotoxicities on adult cancer survivors’ symptom burden and quality of life , 2018, Journal of Cancer Survivorship.

[8]  G. Kaspers,et al.  CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer , 2018, Pediatric blood & cancer.

[9]  K. Kidwell,et al.  Abstract P6-11-03: Association of systemic paclitaxel concentrations with severity and progression of paclitaxel-induced peripheral neuropathy , 2018 .

[10]  Lara E Sucheston-Campbell,et al.  Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci , 2018, Pharmacogenetics and genomics.

[11]  H. Goldschmidt,et al.  Bortezomib‐induced peripheral neuropathy: A genome‐wide association study on multiple myeloma patients , 2018, Hematological oncology.

[12]  Lara E Sucheston-Campbell,et al.  OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity , 2018, The Journal of clinical investigation.

[13]  P. Austin,et al.  Neurotoxicity Outcomes in a Population‐based Cohort of Elderly Patients Treated With Adjuvant Oxaliplatin for Colorectal Cancer , 2017, Clinical colorectal cancer.

[14]  N. Puig,et al.  Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array , 2017, Hematological oncology.

[15]  M. Schmidt,et al.  Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy , 2017, Oncotarget.

[16]  J. Wu,et al.  Single nucleotide polymorphisms of nucleotide excision repair pathway are significantly associated with outcomes of platinum-based chemotherapy in lung cancer , 2017, Scientific Reports.

[17]  J. Hallas,et al.  Clopidogrel–Paclitaxel Drug–Drug Interaction: A Pharmacoepidemiologic Study , 2017, Clinical pharmacology and therapeutics.

[18]  I. Vetter,et al.  Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy , 2017, Front. Mol. Neurosci..

[19]  M. Yamazaki,et al.  Increased risk of paclitaxel-induced peripheral neuropathy in patients using clopidogrel: a retrospective pilot study , 2017, Journal of Anesthesia.

[20]  Cheng Cheng,et al.  An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine‐Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia , 2017, Clinical pharmacology and therapeutics.

[21]  P. Dougherty,et al.  Disease burden and pain in obese cancer patients with chemotherapy-induced peripheral neuropathy , 2017, Supportive Care in Cancer.

[22]  Ling Huang,et al.  Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer , 2017, BMC Gastroenterology.

[23]  Enrique J. deAndrés-Galiana,et al.  Sensitivity analysis of gene ranking methods in phenotype prediction , 2016, J. Biomed. Informatics.

[24]  J. Wikel,et al.  Identification and Characterization of New Chemical Entities Targeting Apurinic/Apyrimidinic Endonuclease 1 for the Prevention of Chemotherapy-Induced Peripheral Neuropathy , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[25]  H. Guchelaar,et al.  Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients , 2016, British Journal of Cancer.

[26]  Lang Li,et al.  Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans , 2016, Oncotarget.

[27]  N. Reinmuth,et al.  Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  Jason D. Wright,et al.  Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Ulaşlı,et al.  Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel , 2016, OncoTargets and therapy.

[30]  M. Meisler,et al.  Biallelic Mutations of VAC14 in Pediatric-Onset Neurological Disease. , 2016, American journal of human genetics.

[31]  A. Hucke,et al.  The Role of Transporters in the Toxicity of Chemotherapeutic Drugs: Focus on Transporters for Organic Cations , 2016, Journal of clinical pharmacology.

[32]  Ivo D. Shterev,et al.  Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy , 2016, Clinical Cancer Research.

[33]  P. Sonneveld,et al.  A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma , 2016, Clinical Cancer Research.

[34]  E. Lopez-Lopez,et al.  Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population. , 2016, Pharmacogenetics and genomics.

[35]  A. Abyzov,et al.  Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance) , 2016, Cancer medicine.

[36]  S. W. Lam,et al.  Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review. , 2015, Cancer treatment reviews.

[37]  S. Züchner,et al.  Association of the Charcot–Marie–Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance) , 2015, Journal of the Neurological Sciences.

[38]  T. Therneau,et al.  RWDD3 and TECTA variants not linked to paclitaxel induced peripheral neuropathy in North American trial Alliance N08C1 , 2015, Acta oncologica.

[39]  Daniel L. Koller,et al.  Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199 , 2015, Clinical Cancer Research.

[40]  M. Ewertz,et al.  Docetaxel-induced neuropathy: A pharmacogenetic case-control study of 150 women with early-stage breast cancer , 2015, Acta oncologica.

[41]  N. Staff,et al.  Candidate pathway-based genetic association study of platinum and platinum–taxane related toxicity in a cohort of primary lung cancer patients , 2015, Journal of the Neurological Sciences.

[42]  T. Ng,et al.  The genetic variants underlying breast cancer treatment-induced chronic and late toxicities: a systematic review. , 2014, Cancer treatment reviews.

[43]  Gillian L. Currie,et al.  Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis , 2014, PAIN®.

[44]  M. White-Koning,et al.  Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and , 2014, Cancer Chemotherapy and Pharmacology.

[45]  L. Carey,et al.  Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy , 2014, Breast Cancer Research and Treatment.

[46]  J. Albers,et al.  Interventions for preventing neuropathy caused by cisplatin and related compounds. , 2014, The Cochrane database of systematic reviews.

[47]  C. Caldas,et al.  Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel , 2014, Clinical Cancer Research.

[48]  Yu Yin,et al.  XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis , 2014, Tumor Biology.

[49]  J. Mefford,et al.  Polygenic Inheritance of Paclitaxel-Induced Sensory Peripheral Neuropathy Driven by Axon Outgrowth Gene Sets in CALGB 40101 (Alliance) , 2014, The Pharmacogenomics Journal.

[50]  J. Aparicio,et al.  Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  A. Shields,et al.  Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2 , 2013, Proceedings of the National Academy of Sciences.

[52]  W. Vach,et al.  GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients , 2013, Acta oncologica.

[53]  C. Heckler,et al.  Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study , 2013, Supportive Care in Cancer.

[54]  J. Duley,et al.  Vincristine pharmacodynamics and pharmacogenetics in children with cancer: A limited‐sampling, population modelling approach , 2011, Journal of paediatrics and child health.

[55]  N. André,et al.  Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity , 2011, Cancer Chemotherapy and Pharmacology.

[56]  A. Navarro,et al.  Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide. , 2011, Leukemia research.

[57]  Daniel L. Koller,et al.  Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  D. Esseltine,et al.  Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. , 2011, The Lancet. Oncology.

[59]  S. Clarke,et al.  Pharmacometabonomic Profiling as a Predictor of Toxicity in Patients with Inoperable Colorectal Cancer Treated with Capecitabine , 2011, Clinical Cancer Research.

[60]  H. Goldschmidt,et al.  Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  G. Mulligan,et al.  Genetic variation associated with bortezomib-induced peripheral neuropathy , 2011, Pharmacogenetics and genomics.

[62]  S. Hall,et al.  Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia , 2011, Pediatric blood & cancer.

[63]  Xianglin L. Du,et al.  Risk of Chemotherapy-Induced Peripheral Neuropathy in Large Population-Based Cohorts of Elderly Patients With Breast, Ovarian, and Lung Cancer , 2010, American journal of therapeutics.

[64]  T. Miyazaki,et al.  Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study , 2010, International Journal of Clinical Oncology.

[65]  J. Ioannidis,et al.  STrengthening the REporting of Genetic Association Studies (STREGA)— An Extension of the STROBE Statement , 2009, PLoS medicine.

[66]  Robert Brown,et al.  Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[68]  A. Argyriou,et al.  Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? , 2006, Supportive Care in Cancer.

[69]  Kenneth C Anderson,et al.  Lenalidomide and thalidomide: mechanisms of action--similarities and differences. , 2005, Seminars in hematology.

[70]  S. Steinberg,et al.  Association of Paclitaxel Pharmacokinetics with the Development of Peripheral Neuropathy in Patients with Advanced Cancer , 2005, Clinical Cancer Research.

[71]  H. Ozçelik,et al.  Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[72]  Richard LeBlanc,et al.  Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. , 2002, Blood.

[73]  S. Chaney,et al.  Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity. , 2002, Anticancer research.

[74]  David G. Wilkinson,et al.  Multiple roles of eph receptors and ephrins in neural development , 2001, Nature Reviews Neuroscience.

[75]  M. Weinfeld,et al.  XRCC1 Stimulates Human Polynucleotide Kinase Activity at Damaged DNA Termini and Accelerates DNA Single-Strand Break Repair , 2001, Cell.

[76]  D. Stewart,et al.  Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  L. Einhorn,et al.  Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  L. Vitetta,et al.  New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy , 2016, Asia-Pacific journal of oncology nursing.

[79]  J. Albers,et al.  Interventions for preventing neuropathy caused by cisplatin and related compounds. , 2011, The Cochrane database of systematic reviews.